Polio and Polio Vaccine

Donna L. Weaver, RN, MN
Nurse Educator

Pink Book Webinar Series
August 10, 2016
Poliomyelitis Disease

- First outbreak described in the U.S. in 1843
- More than 21,000 paralytic cases reported in the U.S. in 1952
- Global eradication within this decade
Poliovirus

- Three serotypes of wild polio virus:
  - WPV1
  - WPV2
  - WPV3

- Minimal heterotypic immunity between serotypes

- Rapidly inactivated by heat, chlorine, formaldehyde, and ultraviolet light
Poliomyelitis Pathogenesis

- Entry into mouth
- Replication in pharynx and GI tract
- Hematologic spread to lymphatics and central nervous system
- Viral spread along nerve fibers
- Destruction of motor neurons

Racaniello VR. One hundred years of poliovirus pathogenesis. *Virology* 2006;344:9-16
Outcomes of Poliovirus Infection

- Asymptomatic
- Minor non-specific illness
- Aseptic meningitis
- Flaccid paralysis
Poliovirus Epidemiology

- **Reservoir**: Human
- **Transmission**: Fecal-oral, Oral-oral possible
- **Communicability**: Most infectious: 7-10 days before onset, Virus present in stool 3-6 weeks
Poliomyelitis—United States, 1950-2011

Source: National Notifiable Disease Surveillance System, CDC
Poliomyelitis—United States, 1980-2010

Vaccine–associated paralytic polio = VAPP

Cases


VAPP  Imported
Poliovirus Vaccines

- 1955 - Inactivated vaccine
- 1963 - Trivalent OPV
- 1987 – Enhanced-potency (IPV)
Inactivated Polio Vaccine

- Highly effective in producing immunity to poliovirus
  - $\geq 90\%$ of recipients immune after 2 doses
  - $\geq 99\%$ of recipients immune after 3 doses
- Duration of immunity not known with certainty
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2016. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV) / RV1 / (2-dose series)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP: &lt;7 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV; &lt;18 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IV; LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal (MenACWY-D &lt;6 mos; MenACWY-CRM ≥ 2 mos)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (Tdap: ≥7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV; females only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B (MenB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Range of recommended ages for all children**

**Range of recommended ages for catch-up immunization**

**Range of recommended ages for certain high-risk groups**

**Range of recommended ages for non-high-risk groups that may receive vaccine, subject to individual clinical decision making**

**No recommendation**

This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at [http://www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html). Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ([http://www.vaers.hhs.gov](http://www.vaers.hhs.gov)) or by telephone (800-822-7967). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online ([http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.htm](http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.htm)) or by telephone (800-CDC-INFO [800-232-4636]).

This schedule is approved by the Advisory Committee on Immunization Practices ([http://www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)), the American Academy of Pediatrics ([http://www.aap.org](http://www.aap.org)), the American Academy of Family Physicians ([http://www.aafp.org](http://www.aafp.org)), and the American College of Obstetricians and Gynecologists ([http://www.acog.org](http://www.acog.org)).

NOTE: The above recommendations must be read along with the footnotes of this schedule.
<table>
<thead>
<tr>
<th>IPV Dose</th>
<th>Routinely Recommended at</th>
<th>Minimum Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2 months of age</td>
<td>4 weeks</td>
</tr>
<tr>
<td>2</td>
<td>4 months of age</td>
<td>4 months</td>
</tr>
<tr>
<td>3</td>
<td>6-18 months of age</td>
<td>6 months</td>
</tr>
<tr>
<td>4</td>
<td>4-6 years of age</td>
<td>6 months</td>
</tr>
</tbody>
</table>
Catch-up IPV Vaccination

- In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus.
- If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose.
- A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.

Schedules that Include Both IPV and OPV

- Only IPV is available in the United States

- If both OPV and IPV were administered as part of a series, the series should be completed with IPV. Any combination of 4 doses of OPV and IPV by 4 to 6 years of age constitutes a complete series

- If only OPV doses were administered, and all doses were given prior to 4 years of age, one dose of IPV should be given at 4 years or older, at least 4 weeks after the last OPV dose
Poliovirus-containing Vaccine Products

- **Single component vaccine - IPV (IPOL)**

- **FOUR polio-containing combination vaccine products:**
  - DTaP-IPV/Hib (Pentacel)
  - DTaP-HepB-IPV (Pediarix)
  - DTaP-IPV (Kinrix)
  - DTaP-IPV (Quadracel)
DTaP-IPV/Hib (Pentacel)

- FDA-approved for:
  - IPV doses 1 through 4
  - Children 6 weeks through 4 years of age

- Use DTaP-IPV diluent to reconstitute the Hib component

Reminder: Only use the manufacturer’s supplied diluent

www.cdc.gov/vaccines/hcp/clinical-resources/downloads/pentacel-delay.pdf
DTaP-HepB-IPV (Pediarix)

- FDA-approved for:
  - IPV doses 1 through 3
  - Children 6 weeks through 6 years of age
DTaP-IPV (Kinrix & Quadracel)

- **Kinrix**
  - IPV dose 4
  - Children 4 through 6 years of age

- **Quadracel**
  - IPV dose 4 or 5
  - 4 through 6 years of age

VA error: Do NOT use to reconstitute the Hib component of Pentacel vaccine
Polio Vaccination of Adolescents and Adults

- **Routine** vaccination of U.S. residents 18 years of age or older is not necessary or recommended

- May consider vaccination of travelers to polio-endemic countries and selected lab workers
Polio Vaccination of Unvaccinated Adults

- Use standard IPV schedule if possible
  - 0, 1-2 months, 6-12 months intervals

- May separate first and second doses by 4 weeks if accelerated schedule needed

- The minimum interval between the second and third doses is 6 months
Polio Vaccination of Previously Vaccinated Adults

- Previously completed series
  - Administer 1 dose of IPV to those at risk

- Incomplete series
  - Administer remaining doses in series based on immunization history

- No need to restart a valid documented series
  - Valid = minimum intervals met
Contraindications and Precautions

- Severe allergic reaction to a vaccine component or following a prior dose of vaccine
- Moderate to severe acute illness
IPV Adverse Reactions

- Local reactions: 2.8% (pain, redness, swelling)

- Severe reactions: rare
Polio Eradication

- Last case in the United States in 1979
- Western Hemisphere certified polio-free in 1994
- Last isolate of WPV2 was in India in October 1999
- Global eradication goal
Global Polio Efforts

- The number of worldwide reported cases has decreased from an estimated 350,000 in 1988 to 19 as of June 29, 2016
- Afghanistan – 6 cases of WPV1
- Pakistan – 13 cases of WPV1
- Nigeria – Polio-free

http://www.polioeradication.org
http://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/en/
Haemophilus influenzae Type b and Hib Vaccine
Haemophilus influenzae

- Severe bacterial infection, particularly among infants
- Aerobic gram-negative bacteria
- Polysaccharide capsule
- 6 different serotypes (a-f) of polysaccharide capsule
- 95% of invasive disease caused by type b (prevaccine era)
Impact of *Haemophilus influenzae* Type b Disease

- Formerly the leading cause of bacterial meningitis among children younger than 5 years of age
- Approximately 1 in 200 children developed invasive Hib disease
- Almost all infections among children younger than 5 years
Haemophilus influenzae Type b
Clinical Manifestations*

- Meningitis: 50%
- Epiglottitis: 17%
- Pneumonia: 15%
- Osteomyelitis: 2%
- Arthritis: 8%
- Cellulitis: 6%
- Bacteremia: 2%

*Prevaccine era
Hib facial cellulitis
*Haemophilus influenzae* Type b Epidemiology

- **Reservoir**: Human asymptomatic carriers
- **Transmission**: Respiratory droplets presumed
- **Temporal pattern**: Peaks in Sept-Dec and March-May
- **Communicability**: Generally limited but higher in some circumstances (e.g., household, child care)
Estimated Annual Incidence (per 100,000) of Invasive *Haemophilus influenzae* Type b (Hib) Disease in Children Aged <5 Years — United States, 1980–2012

Haemophilus influenzae, Invasive Disease
Incidence of reported cases (per 100,000), by serotype among children aged <5 years — United States, 2000–2013

Haemophilus influenzae Type b Polysaccharide Vaccine

- Available 1985-1988
- Not effective in children younger than 18 months of age
- Efficacy in older children varied
- Age-dependent immune response
- Not consistently immunogenic in children 2 years of age and younger
- No booster response
Haemophilus influenzae Type b Conjugate Vaccines

- Conjugation improves immunogenicity
  - Immune response with booster doses
- Same polysaccharide capsule linked to different carrier proteins
- 3 monovalent conjugate vaccines
- 2 combination vaccines available that contain Hib vaccine
Conjugate Hib Vaccines

- PRP-T
  - ActHIB
  - Hiberix
  - Pentacel
  - MenHibrix

- PRP-OMP
  - PedvaxHIB
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2016.
(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19–22 mos</th>
<th>2–3 yrs</th>
<th>4–6 yrs</th>
<th>7–10 yrs</th>
<th>11–12 yrs</th>
<th>13–15 yrs</th>
<th>16–18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV/RV1/2-dose series); RSV (3-dose series)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP-Rd, 7-yr)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haemophilus influenzae type b</strong> (Hib)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td>3rd or 4th dose</td>
<td>See footnote 4</td>
<td>See footnote 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>(PCV13)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>(IPV - &lt;18 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>(IV, LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (IV IV) 1 or 2 doses</td>
<td>Annual vaccination (LAIV or IV) 1 or 2 doses</td>
<td>Annual vaccination (LAIV or IV) 1–dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>(MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>(VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2-dose series</td>
<td>See footnote 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal C (Hib-MenCY ≥ 6 weeks; MenACWY-D ≥ 9 mos; MenACWY-CRM ≥ 2 mos)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td>5th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis</td>
<td>(Tdap ≥ 7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>(2-dose series; females only; 4vHPV, 9vHPV; males and females)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td>4th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td>(MenB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td>(PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td>2nd dose</td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Range of recommended ages for all children | Range of recommended ages for catch-up immunization | Range of recommended ages for certain high-risk groups | Range of recommended ages for non-high-risk groups | No recommendation |

This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at [http://www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html). Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ([http://vaers.hhs.gov](http://vaers.hhs.gov)) or by telephone (800-822-7967). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online ([http://www.cdc.gov/vaccines/recs/vac-admin/contraindication.htm](http://www.cdc.gov/vaccines/recs/vac-admin/contraindication.htm)) or by telephone (800-CDC-INFO (800-232-4636)).

This schedule is approved by the Advisory Committee on Immunization Practices ([http://www.cdc.gov/vaccines/acip](http://www.cdc.gov/vaccines/acip)), the American Academy of Pediatrics ([http://www.aap.org](http://www.aap.org)), the American Academy of Family Physicians ([http://www.aafp.org](http://www.aafp.org)), and the American College of Obstetricians and Gynecologists ([http://www.acog.org](http://www.acog.org)).

**NOTE:** The above recommendations must be read along with the footnotes of this schedule.
Hib Vaccine

- Recommended interval 8 weeks for primary series
- Minimum interval 4 weeks for primary series
- Minimum age 6 weeks
- Booster dose at 12-15 months
## Hib Vaccine Routine Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12-18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRP-T</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PRP-OMP</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>X</td>
</tr>
</tbody>
</table>
Unvaccinated Children 7 months of Age and Older

- Children starting late may not need entire 3 or 4 dose series
- Number of doses child requires depends on current age
- See detailed schedule p. 128 of Pink Book, and 2016 catch-up schedule
Hib Vaccine
Use in Older Children and Adults

- Generally not recommended for persons older than 59 months of age

- High-risk older children and adolescents may be vaccinated if not vaccinated in childhood
  - Asplenia
  - Immunodeficiency
  - HIV infection
  - Receipt of chemotherapy or radiation therapy

- Special populations
### Guidance for Hib Vaccination in High-risk Groups

<table>
<thead>
<tr>
<th>High-risk group</th>
<th>Hib vaccine guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elective splenectomy</td>
<td>If unimmunized: 1 dose, prior to procedure</td>
</tr>
<tr>
<td>Asplenic patient</td>
<td>If unimmunized: 1 dose</td>
</tr>
<tr>
<td>HIV-infected children</td>
<td>If unimmunized: 1 dose</td>
</tr>
<tr>
<td>HIV-infected adults</td>
<td>Hib vaccination not recommended</td>
</tr>
<tr>
<td>Hematopoietic cell transplant</td>
<td>3 doses (at least 4 weeks apart) beginning 6-12 months after transplant</td>
</tr>
</tbody>
</table>
Special Populations

- **Children aged <24 months with invasive Hib disease**
  - Administer complete series as recommended for child’s age
  - Vaccinate during the convalescent phase of the illness

- **American Indian/Alaska Natives**
  - PRP-OMP vaccines specifically recommended for primary series doses
  - Hib disease peaks earlier in infancy
  - PRP-OMP vaccines produce protective antibody after first dose/early protection
Monovalent Hib Vaccines

- ActHIB (PRP-T)
- Hiberix (PRP-T)
- PedvaxHIB (PRP-OMP)
ActHIB (PRP-T)

- Approved for all doses of primary schedule and booster dose
- Can be used for previously unvaccinated children per the catch-up schedule
- Must be reconstituted only with 0.4% sodium chloride (NaCl) ActHIB diluent
Hiberix (PRP-T)

- Approved for all doses of primary schedule and booster dose
- Can be used for previously unvaccinated children per the catch-up schedule
PedvaxHIB (PRP-OMP)

- Approved for all doses of primary schedule and booster dose
  - Remember primary series for PRP-OMP vaccines is 2 doses
- Can be used for previously unvaccinated children per the catch-up schedule
Hib-containing Combination Vaccines

- DTaP- IPV/Hib (Pentacel)
- Hib-MenCY (MenHIBrix)
Pentacel

- Contains DTaP, Hib (PRP-T), and IPV
- Approved for doses 1 through 4 among children 6 weeks through 4 years of age
- Do NOT use for children 5 years or older
- Package contains lyophilized Hib (ActHIB) that is reconstituted with a liquid DTaP-IPV solution
MenHibrix

- Contains Hib (PRP-T) and *Neisseria meningitidis* serogroups C and Y
- Approved for 4 doses between 6 weeks and 18 months of age
- Only recommended for routine meningococcal vaccination of infants who are at increased risk for meningococcal disease
  - Persistent complement pathway deficiencies
  - Anatomic or functional asplenia, including sickle cell disease
Hib Vaccine Interchangeability

- All monovalent conjugate Hib vaccines are interchangeable for primary series and booster dose

- 3-dose primary series (4 doses total) if more than one brand of vaccine used at 2 or 4 months of age

- Whenever feasible use same combination vaccine for subsequent doses

- If vaccine used for earlier doses is not known or not available, any brand may be used to complete the series
Comvax

- Hepatitis B-Hib (PRP-OMP) combination
- Removed from existing contracts and pricing programs
- Listed as “Discontinued” on FDA website
- Last supplies expected to expire August 19, 2016
Contraindications and Precautions

- Severe allergic reactions to vaccine component or following previous dose
- Moderate to severe acute illness
- Age younger than 6 weeks
Hib Vaccine Adverse Reactions

- Swelling, redness, or pain in 5%-30% of recipients
- Systemic reactions infrequent
- Serious adverse reactions rare